Acute Kidney Injury Following Aortic Valve Replacement in Patients Without Chronic Kidney Disease

TLDR: TAVR in patients without CKD was associated with a significantly less frequent incidence of AKI compared with SAVR, and increasing severity ofAKI was incrementally associated with 5-year mortality.

About: This article is published in Canadian Journal of Cardiology.The article was published on 2021-01-01 and is currently open access. It has received 7 citations till now. The article focuses on the topics: Kidney disease & Aortic valve replacement.

Figures

Table 5. The incidence of AKI according to the bleeding severities and units of transfusion

Figure 4. The impact of AKI severities on 5-year mortality

Table 1. Baseline characteristics before propensity score matching

Table 3. Procedure characteristics and early outcomes

Table 2. Baseline characteristics after propensity score matching

Table 6. Multivariable analysis of factors associated with 5-year mortality

Frequently asked questions

Q1. What are the contributions mentioned in the paper "Acute kidney injury following aortic valve replacement in patients without chronic kidney disease moriyama, noriaki" ?

Moriyama et al. this paper investigated the incidence and predictors of acute kidney injury following aortic valve replacement in patients without chronic kidney disease. 

Q2. What was the significance of TAVR in patients with CKD?

Ourfindings demonstrated that patients who underwent TAVR had a significantly lower incidence of AKIin comparison to those who underwent SAVR, and TAVR was associated with decreasing incidence ofAKI during study periods. 

Q3. What was the significance of the TAVR and SAVR?

AKI significantly increased the risk of 5-year mortality aftereither TAVR or SAVR and increasing severity of AKI was incrementally associated with 5-yearmortality. 

Q4. What was the significance of the TAVR in patients without CKD?

Patients withAKI had significantly increased 5-year mortality compared to those without AKI (unmatched 36.0%vs 19.1%, log-rank P<0.001; matched 36.3% vs 24.0%, log-rank P<0.001). 

Q5. What is the name of the registry?

Clinical Trial Registration: ClinicalTrials.gov, Identifier: NCT03385915.(URL https://clinicaltrials.gov/ct2/show/NCT03385915)4From the nationwide registry, 4555 consecutive patients with pre-procedural normal kidneyfunction who underwent TAVR and SAVR (TAVR, n=1215 and SAVR, n=3340) were evaluated. 

Q6. What was the hazard ratio for TAVR in patients without CKD?

The adjusted hazard ratiosfor 5-year mortality were 1.58 (95%CI 1.20-2.08) for AKI grade 1, 3.27 (95%CI 2.09-5.06) for grade 2and 4.82 (95%CI 2.93-8.04) for grade 3.3Conclusions: TAVR in patients without CKD was associated with significantly less frequentincidence of AKI compared with SAVR.